Stay updated on Aripiprazole Lauroxil in Schizophrenia Relapse Prevention Clinical Trial
Sign up to get notified when there's something new on the Aripiprazole Lauroxil in Schizophrenia Relapse Prevention Clinical Trial page.

Latest updates to the Aripiprazole Lauroxil in Schizophrenia Relapse Prevention Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedNew revision entry v3.3.2 appears in Study Record Versions, and v3.2.0 is no longer listed. The updates reflect revision history and QC status details. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check22 days agoChange DetectedThe top government funding notice banner has been removed, and the study record content remains unaffected; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.7%

- Check43 days agoChange DetectedRoutine version updates are shown in the record history and do not modify the core trial details; no new information affecting eligibility, interventions, or outcomes is introduced, and to avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check65 days agoChange DetectedCore content updated to v3.2.0 with a government-operating-status notice and a removal of the previous v3.1.0 marker.SummaryDifference12%

- Check72 days agoChange Detected- The page now shows Revision: v3.1.0, replacing the previous v3.0.2.SummaryDifference0.3%

- Check86 days agoChange DetectedThe page was updated to revision v3.0.2 and the Back to Top element was removed.SummaryDifference0.7%

Stay in the know with updates to Aripiprazole Lauroxil in Schizophrenia Relapse Prevention Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Aripiprazole Lauroxil in Schizophrenia Relapse Prevention Clinical Trial page.